The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Zgoda V.G.

Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia

Tikhonova O.V.

Endocrinology Research Centre, Moscow, Russia

Malyavskaya S.I.

SevGMU 'Northern State Medical University' of the Ministry of Health of Russia, Arkhangelsk, Russia

Cerebrolysin peptides as mood stabilizers

Authors:

Torshin I.Iu., Gromova O.A., Zgoda V.G., Tikhonova O.V., Malyavskaya S.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12): 69‑75

DOI: 10.17116/jnevro201911912169

Read: 12074 times

Download PDF (RU)
Contact the author
Table of contents

CEREBROLYSIN PEPTIDES AS MOOD STABILIZERS
CEREBROLYSIN PEPTIDES AS MOOD STABILIZERS

To cite this article:

Torshin IIu, Gromova OA, Zgoda VG, Tikhonova OV, Malyavskaya SI. Cerebrolysin peptides as mood stabilizers. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12):69‑75. (In Russ.)
https://doi.org/10.17116/jnevro201911912169

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cere­brolysin in the preventive therapy of deme­ntia in elde­rly patients with mild cognitive impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):51-59
Cere­brolysin and the opti­mal timing of anti­coagulation resu­mption in stroke: combined post hoc survival analysis of the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):77-93
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117
The blood content of 25-OH vita­min D and biogenic amines in resi­dents of Arkhangelsk city. Russian Journal of Preventive Medi­cine. 2024;(11):108-114
Neurometabolic therapy with Cere­brolysin in patients with sepsis-associated ence­phalopathy. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):46-54
Abstract:

Objective. To establish the molecular mechanisms of the mood stabilizing (normothymic) action of the neuroprotector Cerebrolysin. Material and methods. Mass-spectrometric analysis of the peptide composition of cerebrolysin followed by a complex bioinformatics analysis was utilized. Results. Cerebrolysin contains considerable amounts of Leu- and Met-enkephalins, partial analogues of enkephalins, peptide fragments of beta-lipotropin. These peptides stimulate the endorphinergic system thus contributing to normothymic action and an increase in the levels of the brain-derived neurotrophic factor (BDNF). Specific inhibition of kinases ABL1, PINK1, CDK5 and arginine N-methyltransferase PRMT5 by the peptides of cerebrolysin has a multidirectional effect on the dopaminergic system, also helping to stabilize mood. Cerebrolysin peptides do not directly affect neither the serotonergic, adrenergic, nor GABAergic systems. Conclusions. The normothymic effect of Cerebrolysin is due to the stabilization of endorphinergic and dopaminergic neurotransmission.

Keywords:

enkephalins
dopamine
neuroprotectors
bioinformatics
cerebrolysin

Authors:

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Zgoda V.G.

Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia

Tikhonova O.V.

Endocrinology Research Centre, Moscow, Russia

Malyavskaya S.I.

SevGMU 'Northern State Medical University' of the Ministry of Health of Russia, Arkhangelsk, Russia

Close metadata

References:

  1. Parfenov VA. Poststroke depression: prevalence, pathogenesis, diagnosis, and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(4):84-88. (In Russ.) https://doi.org/10.14412/2074-2711-2012-428
  2. Psychiatry. National guideline. Alexandrovsky YuA, Neznanov NG, eds. 2018. (In Russ.)
  3. Chemer N, Bilanovskyi V. Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives. Neurol Ther. 2019;8(1):25-27. Epub 2019 Feb 18. PMID:30778859. https://doi.org/10.1007/s40120-019-0128-1
  4. Rokhlina ML, Kozlov AA, Usmanova NN, Smirnova EA. The use of cerebrolysin in heroin addiction. Psihiatrija i Psihofarmakoterapija. 2001;3:98-102. (In Russ.)
  5. Gromova OA, Torshin IYu, Zgoda VG, Tikhonova OV. Complex proteomic analysis of the «light» peptide fraction of the drug Cerebrolysin. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119(8):75-83. (In Russ.) https://doi.org/10.17116/jnevro201911908175
  6. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47(1):506-515. PMID:30395287. https://doi.org/10.1093/nar/gky1049
  7. Torshin IYu. Sensing the change from molecular genetics to personalized medicine. Ed. Gromova O.A. Nova Biomedical Books. In: Bioinformatics in the Post-Genomic Era. NY, USA. 2009.
  8. Torshin IYu. Bioinformatics in the post-genomic era: physiology and medicine. NY, USA. Nova Biomedical Books. 2007.
  9. Shimanovsky NL, Gurevich KG. Biochemical pharmacology of opioid receptors. Nejrohimija. 2000;17(4);259-266. (In Russ.)
  10. Sanguinetti AR, Mastick CC. c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal. 2003;15(3):289-298. PMID:12531427.
  11. Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, Singleton PA, Wang L, Desai A, Arce FT, Lal R, Van Eyk JE, Imam SZ, Garcia JG. Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell. 2010;21(22):4042-4056. Epub 2010 Sep 22. PMID: 20861316. https://doi.org/10.1091/mbc.E09-10-0876
  12. Jeong J, Park YU, Kim DK, Lee S, Kwak Y, Lee SA, Lee H, Suh YH, Gho YS, Hwang D, Park SK. Cdk5 phosphorylates dopamine D2 receptor and attenuates downstream signaling. PLoS One. 2013;8(12):e84482. eCollection 2013. PMID: 24391960. https://doi.org/10.1371/journal.pone.0084482
  13. Munoz JP, Huichalaf CH, Orellana D, Maccioni RB. cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal cells. J Cell Biochem. 2007;100(3):738-749. PMID: 17009320. https://doi.org/10.1002/jcb.21041
  14. Likhite N, Jackson CA, Liang MS, Krzyzanowski MC, Lei P, Wood JF, Birkaya B, Michaels KL, Andreadis ST, Clark SD, Yu MC, Ferkey DM. The protein arginine methyltransferase PRMT5 promotes D2-like dopamine receptor signaling. Sci Signal. 2015;8(402):115. PMID: 26554819. https://doi.org/10.1126/scisignal.aad0872
  15. Skoubis PD, Lam HA, Shoblock J, Narayanan S, Maidment NT. Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci. 2005;21(5):1379-1384. PMID: 15813947. https://doi.org/10.1111/j.1460-9568.2005.03956.x
  16. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. Opiates as antidepressants. Curr Pharm Des. 2009;15(14):1612-1622. PMID: 19442177. https://doi.org/10.2174/138161209788168100
  17. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, Li QF, Jeffry J, Kim JY, Loh HH, Chen ZF. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell. 2011;147(2):447-458. PMID: 22000021. https://doi.org/10.1016/j.cell.2011.08.043
  18. Colaianni L, Kung SC, Taggart DK, Picca RA, Greaves J, Penner RM, Cioffi N. Reduction of spectral interferences using ultraclean gold nanowire arrays in the LDI-MS analysis of a model peptide. Anal Bioanal Chem. 2014;406(19):4571-4583. Epub 2014 Jul 1. PMID: 24980599. https://doi.org/10.1007/s00216-014-7876-7
  19. Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006;1069(1):172-181. Epub 2005 Dec 20. PMID: 16364263. https://doi.org/10.1016/j.brainres.2005.11.005
  20. Leung KM, Hui PK, Chan WY, Thomas TM. Helicobacter pylori-related gastritis and gastric ulcer. A continuum of progressive epithelial degeneration. Am J Clin Pathol. 1992;98(6):569-574. PMID: 1462954. https://doi.org/10.1093/ajcp/98.6.569
  21. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood). 2008;233(8):968-979. Epub 2008 May 14. PMID: 18480416. https://doi.org/10.3181/0802-RM-58
  22. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45(2):330-334. PMID: 8114680.
  23. Dripps IJ, Jutkiewicz EM. Delta Opioid Receptors and Modulation of Mood and Emotion. Handb Exp Pharmacol. 2018;247:179-197. PMID: 28993835. https://doi.org/10.1007/164_2017_42
  24. Genazzani AR, Nappi G, Facchinetti F, Mazzella GL, Parrini D, Sinforiani E, Petraglia F, Savoldi F. Central deficiency of beta-endorphin in alcohol addicts. J Clin Endocrinol Metab. 1982;55:3:583-586.
  25. Thanawala V, Kadam VJ, Ghosh R. Enkephalinase inhibitors: potential agents for the management of pain. Curr Drug Targets. 2008;9(10):887-894. PMID: 18855623.
  26. Henry MS, Gendron L, Tremblay ME, Drolet G. Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience. Neural Plast. 2017;1546125. Epub 2017 Jul 11. PMID: 28781901. https://doi.org/10.1155/2017/1546125
  27. Meyerson FZ, Pshennikova MG. Stress-limiting body systems. Adaptation to stressful situations and physical activity. M.: Medicina; 1988. (In Russ.)
  28. Toubia T, Khalife T. The Endogenous Opioid System: Role and Dysfunction Caused by Opioid Therapy. Clin Obstet Gynecol. 2019;62(1):3-10. PMID: 30398979. https://doi.org/10.1097/GRF.0000000000000409
  29. Hegadoren KM, O’Donnell T, Lanius R, Coupland NJ, Lacaze-Masmonteil N. The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides. 2009;43(5):341-353.
  30. Mørck Nielsen H, Rømer Rassing M. TR146 cells grown on filters as a model of human buccal epithelium: V. Enzyme activity of the TR146 cell culture model, human buccal epithelium and porcine buccal epithelium, and permeability of leu-enkephalin. Int J Pharm. 2000 May 10;200(2):261-70. PubMed PMID: 10867256.
  31. Motel WC, Coop A, Cunningham CW. Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer’s disease. Mini Rev Med Chem. 2013;13(3):456-466. Review. PubMed PMID: 22931533; PubMed Central PMCID: PMC3816933.
  32. Li CH, Chung D. Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. Proc Natl Acad Sci USA. 1976;73(4):1145-1148. PMID: 1063395. https://doi.org/10.1073/pnas.73.4.1145
  33. Lazarus LH, Ling N, Guillemin R. beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins. Proc Natl Acad Sci USA. 1976;73(6):2156-2159. PMID: 1064883. https://doi.org/10.1073/pnas.73.6.2156
  34. Levin YaI. Neurochemical medicine. Part II. Clinical models of the pathology of cerebral dopaminergic systems. Sovremennaja Terapija Psihicheskih Rasstrojstv. 2008;2:4-9. (In Russ.)
  35. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III — the final common pathway. Schizophr Bull. 2009;35(3):549-562. PMID: 19325164. https://doi.org/10.1093/schbul/sbp006
  36. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry. 1992;33(2):115-120. PMID: 1347497.
  37. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep. 2014;4:4874. PMID: 24786396. https://doi.org/10.1038/srep04874
  38. Price DA, Sorkin A, Zahniser NR. Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity. Mol Pharmacol. 2009;76(4):812-823. Epub 2009 Jul 23. PMID: 19628755. https://doi.org/10.1124/mol.109.056978
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.